Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study

NCT00747097 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

43

Enrollment

OTHER

Sponsor class

Conditions

Time to Progression

Interventions

DRUG: gemcitabine + cetuximab

Sponsor

Cliniques universitaires Saint-Luc- Université Catholique de Louvain

Collaborators

[object Object]